Mercy Health launches new trial to reduce chemo nerve damage
Peak of Ohio • • health
Key Points:
- Mercy Health’s Springfield and Urbana Cancer Centers have launched a clinical trial testing the Lilac Glove & Boot device to reduce chemotherapy-induced peripheral neuropathy (CIPN), a common and painful side effect causing nerve damage in patients' hands and feet.
- The device applies gentle pressure during chemotherapy to limit drug exposure to nerves, potentially preventing symptoms like numbness, tingling, pain, and weakness that can affect daily activities.
- The IMPACT clinical trial, conducted with the device developer Luminate, compares the active compression device against a control to evaluate its effectiveness in preserving nerve function during treatment.
- Patients participating in the trial receive close monitoring of symptoms and contribute to research aimed at improving supportive care for cancer patients facing neuropathy.
- Mercy Health emphasizes this trial as part of its ongoing commitment to advanced, accessible cancer care in the Springfield area, encouraging eligible patients to discuss participation with their oncology team.
